nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—AOX1—Methotrexate—urinary bladder cancer	0.213	0.585	CbGbCtD
Zaleplon—CYP3A4—Thiotepa—urinary bladder cancer	0.0703	0.193	CbGbCtD
Zaleplon—CYP3A5—Etoposide—urinary bladder cancer	0.0489	0.134	CbGbCtD
Zaleplon—CYP3A4—Etoposide—urinary bladder cancer	0.0191	0.0522	CbGbCtD
Zaleplon—CYP3A4—Doxorubicin—urinary bladder cancer	0.013	0.0356	CbGbCtD
Zaleplon—CYP3A4—urine—urinary bladder cancer	0.00381	0.077	CbGeAlD
Zaleplon—AOX1—prostate gland—urinary bladder cancer	0.00345	0.0696	CbGeAlD
Zaleplon—TSPO—prostate gland—urinary bladder cancer	0.00294	0.0594	CbGeAlD
Zaleplon—AOX1—seminal vesicle—urinary bladder cancer	0.00292	0.0589	CbGeAlD
Zaleplon—GABRB3—prostate gland—urinary bladder cancer	0.00267	0.054	CbGeAlD
Zaleplon—TSPO—seminal vesicle—urinary bladder cancer	0.00249	0.0503	CbGeAlD
Zaleplon—AOX1—renal system—urinary bladder cancer	0.00235	0.0474	CbGeAlD
Zaleplon—AOX1—urethra—urinary bladder cancer	0.00231	0.0466	CbGeAlD
Zaleplon—TSPO—epithelium—urinary bladder cancer	0.00216	0.0437	CbGeAlD
Zaleplon—TSPO—smooth muscle tissue—urinary bladder cancer	0.00208	0.0421	CbGeAlD
Zaleplon—TSPO—renal system—urinary bladder cancer	0.00201	0.0405	CbGeAlD
Zaleplon—TSPO—urethra—urinary bladder cancer	0.00197	0.0398	CbGeAlD
Zaleplon—AOX1—female reproductive system—urinary bladder cancer	0.00188	0.038	CbGeAlD
Zaleplon—CYP3A5—prostate gland—urinary bladder cancer	0.00182	0.0368	CbGeAlD
Zaleplon—AOX1—vagina—urinary bladder cancer	0.0017	0.0344	CbGeAlD
Zaleplon—TSPO—female reproductive system—urinary bladder cancer	0.00161	0.0324	CbGeAlD
Zaleplon—GABRA2—vagina—urinary bladder cancer	0.00157	0.0317	CbGeAlD
Zaleplon—GABRB3—female reproductive system—urinary bladder cancer	0.00146	0.0295	CbGeAlD
Zaleplon—TSPO—vagina—urinary bladder cancer	0.00145	0.0293	CbGeAlD
Zaleplon—CYP3A5—renal system—urinary bladder cancer	0.00124	0.0251	CbGeAlD
Zaleplon—AOX1—lymph node—urinary bladder cancer	0.0011	0.0222	CbGeAlD
Zaleplon—GABRA2—lymph node—urinary bladder cancer	0.00102	0.0205	CbGeAlD
Zaleplon—TSPO—lymph node—urinary bladder cancer	0.00094	0.019	CbGeAlD
Zaleplon—CYP3A4—renal system—urinary bladder cancer	0.000933	0.0188	CbGeAlD
Zaleplon—CYP3A5—vagina—urinary bladder cancer	0.0009	0.0182	CbGeAlD
Zaleplon—CYP3A4—female reproductive system—urinary bladder cancer	0.000747	0.0151	CbGeAlD
Zaleplon—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000352	0.012	CbGpPWpGaD
Zaleplon—CYP3A5—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000334	0.0114	CbGpPWpGaD
Zaleplon—CYP3A5—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000333	0.0114	CbGpPWpGaD
Zaleplon—Asthma—Doxorubicin—urinary bladder cancer	0.000328	0.000589	CcSEcCtD
Zaleplon—Pollakiuria—Epirubicin—urinary bladder cancer	0.000327	0.000588	CcSEcCtD
Zaleplon—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000327	0.000588	CcSEcCtD
Zaleplon—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000325	0.000583	CcSEcCtD
Zaleplon—Sweating—Methotrexate—urinary bladder cancer	0.000324	0.000582	CcSEcCtD
Zaleplon—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000324	0.000581	CcSEcCtD
Zaleplon—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000323	0.000581	CcSEcCtD
Zaleplon—Paraesthesia—Etoposide—urinary bladder cancer	0.000323	0.00058	CcSEcCtD
Zaleplon—Weight increased—Epirubicin—urinary bladder cancer	0.000323	0.00058	CcSEcCtD
Zaleplon—Haematuria—Methotrexate—urinary bladder cancer	0.000322	0.000579	CcSEcCtD
Zaleplon—Weight decreased—Epirubicin—urinary bladder cancer	0.000321	0.000576	CcSEcCtD
Zaleplon—Dyspnoea—Etoposide—urinary bladder cancer	0.000321	0.000576	CcSEcCtD
Zaleplon—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.00032	0.000574	CcSEcCtD
Zaleplon—Somnolence—Etoposide—urinary bladder cancer	0.00032	0.000574	CcSEcCtD
Zaleplon—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000319	0.000574	CcSEcCtD
Zaleplon—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000319	0.000574	CcSEcCtD
Zaleplon—Epistaxis—Methotrexate—urinary bladder cancer	0.000319	0.000572	CcSEcCtD
Zaleplon—Pneumonia—Epirubicin—urinary bladder cancer	0.000318	0.000571	CcSEcCtD
Zaleplon—Rash—Thiotepa—urinary bladder cancer	0.000316	0.000567	CcSEcCtD
Zaleplon—Bronchitis—Doxorubicin—urinary bladder cancer	0.000315	0.000567	CcSEcCtD
Zaleplon—Dermatitis—Thiotepa—urinary bladder cancer	0.000315	0.000567	CcSEcCtD
Zaleplon—CYP3A7—Biological oxidations—GSTZ1—urinary bladder cancer	0.000315	0.0108	CbGpPWpGaD
Zaleplon—Headache—Thiotepa—urinary bladder cancer	0.000314	0.000563	CcSEcCtD
Zaleplon—Decreased appetite—Etoposide—urinary bladder cancer	0.000313	0.000562	CcSEcCtD
Zaleplon—CYP3A7—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000311	0.0106	CbGpPWpGaD
Zaleplon—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00031	0.000558	CcSEcCtD
Zaleplon—Body temperature increased—Cisplatin—urinary bladder cancer	0.00031	0.000557	CcSEcCtD
Zaleplon—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.00031	0.000557	CcSEcCtD
Zaleplon—Stomatitis—Epirubicin—urinary bladder cancer	0.000308	0.000553	CcSEcCtD
Zaleplon—Constipation—Etoposide—urinary bladder cancer	0.000307	0.000552	CcSEcCtD
Zaleplon—Pain—Etoposide—urinary bladder cancer	0.000307	0.000552	CcSEcCtD
Zaleplon—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000307	0.000552	CcSEcCtD
Zaleplon—Dysuria—Doxorubicin—urinary bladder cancer	0.000307	0.000551	CcSEcCtD
Zaleplon—Sweating—Epirubicin—urinary bladder cancer	0.000303	0.000544	CcSEcCtD
Zaleplon—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000303	0.000544	CcSEcCtD
Zaleplon—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000302	0.0103	CbGpPWpGaD
Zaleplon—Asthenia—Gemcitabine—urinary bladder cancer	0.000302	0.000543	CcSEcCtD
Zaleplon—Haematuria—Epirubicin—urinary bladder cancer	0.000301	0.000541	CcSEcCtD
Zaleplon—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000299	0.000538	CcSEcCtD
Zaleplon—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000299	0.000537	CcSEcCtD
Zaleplon—CYP3A7—Biological oxidations—GSTO2—urinary bladder cancer	0.000298	0.0102	CbGpPWpGaD
Zaleplon—CYP3A7—Biological oxidations—NAT1—urinary bladder cancer	0.000298	0.0102	CbGpPWpGaD
Zaleplon—Weight increased—Doxorubicin—urinary bladder cancer	0.000298	0.000536	CcSEcCtD
Zaleplon—Epistaxis—Epirubicin—urinary bladder cancer	0.000298	0.000536	CcSEcCtD
Zaleplon—Pruritus—Gemcitabine—urinary bladder cancer	0.000298	0.000535	CcSEcCtD
Zaleplon—Nausea—Thiotepa—urinary bladder cancer	0.000297	0.000534	CcSEcCtD
Zaleplon—Weight decreased—Doxorubicin—urinary bladder cancer	0.000297	0.000533	CcSEcCtD
Zaleplon—Feeling abnormal—Etoposide—urinary bladder cancer	0.000296	0.000532	CcSEcCtD
Zaleplon—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000296	0.000532	CcSEcCtD
Zaleplon—CYP3A7—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000294	0.0101	CbGpPWpGaD
Zaleplon—Pneumonia—Doxorubicin—urinary bladder cancer	0.000294	0.000528	CcSEcCtD
Zaleplon—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000294	0.000528	CcSEcCtD
Zaleplon—Pruritus—Fluorouracil—urinary bladder cancer	0.000293	0.000526	CcSEcCtD
Zaleplon—Visual impairment—Methotrexate—urinary bladder cancer	0.000292	0.000525	CcSEcCtD
Zaleplon—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000287	0.000515	CcSEcCtD
Zaleplon—Urticaria—Etoposide—urinary bladder cancer	0.000286	0.000513	CcSEcCtD
Zaleplon—Stomatitis—Doxorubicin—urinary bladder cancer	0.000285	0.000512	CcSEcCtD
Zaleplon—Body temperature increased—Etoposide—urinary bladder cancer	0.000284	0.000511	CcSEcCtD
Zaleplon—Abdominal pain—Etoposide—urinary bladder cancer	0.000284	0.000511	CcSEcCtD
Zaleplon—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000284	0.000511	CcSEcCtD
Zaleplon—Eye disorder—Methotrexate—urinary bladder cancer	0.000283	0.000509	CcSEcCtD
Zaleplon—Tinnitus—Methotrexate—urinary bladder cancer	0.000283	0.000508	CcSEcCtD
Zaleplon—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000282	0.000507	CcSEcCtD
Zaleplon—Asthenia—Cisplatin—urinary bladder cancer	0.000282	0.000506	CcSEcCtD
Zaleplon—Sweating—Doxorubicin—urinary bladder cancer	0.00028	0.000504	CcSEcCtD
Zaleplon—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000279	0.000502	CcSEcCtD
Zaleplon—Haematuria—Doxorubicin—urinary bladder cancer	0.000279	0.000501	CcSEcCtD
Zaleplon—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000277	0.000497	CcSEcCtD
Zaleplon—Epistaxis—Doxorubicin—urinary bladder cancer	0.000276	0.000496	CcSEcCtD
Zaleplon—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000274	0.00938	CbGpPWpGaD
Zaleplon—Immune system disorder—Methotrexate—urinary bladder cancer	0.000274	0.000492	CcSEcCtD
Zaleplon—Dizziness—Fluorouracil—urinary bladder cancer	0.000274	0.000492	CcSEcCtD
Zaleplon—Visual impairment—Epirubicin—urinary bladder cancer	0.000273	0.000491	CcSEcCtD
Zaleplon—CYP3A7—Biological oxidations—UGT2B7—urinary bladder cancer	0.000273	0.00933	CbGpPWpGaD
Zaleplon—Chills—Methotrexate—urinary bladder cancer	0.000272	0.000489	CcSEcCtD
Zaleplon—CYP3A7—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000269	0.00921	CbGpPWpGaD
Zaleplon—Alopecia—Methotrexate—urinary bladder cancer	0.000268	0.000481	CcSEcCtD
Zaleplon—Mental disorder—Methotrexate—urinary bladder cancer	0.000266	0.000477	CcSEcCtD
Zaleplon—Rash—Gemcitabine—urinary bladder cancer	0.000265	0.000477	CcSEcCtD
Zaleplon—Dermatitis—Gemcitabine—urinary bladder cancer	0.000265	0.000477	CcSEcCtD
Zaleplon—Eye disorder—Epirubicin—urinary bladder cancer	0.000265	0.000476	CcSEcCtD
Zaleplon—Tinnitus—Epirubicin—urinary bladder cancer	0.000265	0.000475	CcSEcCtD
Zaleplon—Malnutrition—Methotrexate—urinary bladder cancer	0.000264	0.000474	CcSEcCtD
Zaleplon—Headache—Gemcitabine—urinary bladder cancer	0.000264	0.000474	CcSEcCtD
Zaleplon—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000261	0.000469	CcSEcCtD
Zaleplon—Rash—Fluorouracil—urinary bladder cancer	0.000261	0.000469	CcSEcCtD
Zaleplon—Dermatitis—Fluorouracil—urinary bladder cancer	0.000261	0.000469	CcSEcCtD
Zaleplon—Headache—Fluorouracil—urinary bladder cancer	0.000259	0.000466	CcSEcCtD
Zaleplon—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000259	0.000465	CcSEcCtD
Zaleplon—Dysgeusia—Methotrexate—urinary bladder cancer	0.000258	0.000464	CcSEcCtD
Zaleplon—Asthenia—Etoposide—urinary bladder cancer	0.000258	0.000464	CcSEcCtD
Zaleplon—Immune system disorder—Epirubicin—urinary bladder cancer	0.000256	0.00046	CcSEcCtD
Zaleplon—Back pain—Methotrexate—urinary bladder cancer	0.000255	0.000459	CcSEcCtD
Zaleplon—Chills—Epirubicin—urinary bladder cancer	0.000255	0.000457	CcSEcCtD
Zaleplon—Pruritus—Etoposide—urinary bladder cancer	0.000254	0.000457	CcSEcCtD
Zaleplon—Visual impairment—Doxorubicin—urinary bladder cancer	0.000253	0.000455	CcSEcCtD
Zaleplon—GABRB2—Ion channel transport—TRPV1—urinary bladder cancer	0.000251	0.00858	CbGpPWpGaD
Zaleplon—Alopecia—Epirubicin—urinary bladder cancer	0.000251	0.00045	CcSEcCtD
Zaleplon—Nausea—Gemcitabine—urinary bladder cancer	0.00025	0.000449	CcSEcCtD
Zaleplon—Mental disorder—Epirubicin—urinary bladder cancer	0.000249	0.000447	CcSEcCtD
Zaleplon—Rash—Cisplatin—urinary bladder cancer	0.000247	0.000445	CcSEcCtD
Zaleplon—Dermatitis—Cisplatin—urinary bladder cancer	0.000247	0.000444	CcSEcCtD
Zaleplon—Malnutrition—Epirubicin—urinary bladder cancer	0.000247	0.000444	CcSEcCtD
Zaleplon—Nausea—Fluorouracil—urinary bladder cancer	0.000246	0.000442	CcSEcCtD
Zaleplon—CYP3A7—Biological oxidations—CYP4B1—urinary bladder cancer	0.000246	0.0084	CbGpPWpGaD
Zaleplon—Eye disorder—Doxorubicin—urinary bladder cancer	0.000245	0.000441	CcSEcCtD
Zaleplon—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000245	0.00044	CcSEcCtD
Zaleplon—Tinnitus—Doxorubicin—urinary bladder cancer	0.000245	0.00044	CcSEcCtD
Zaleplon—Anaemia—Methotrexate—urinary bladder cancer	0.000244	0.000438	CcSEcCtD
Zaleplon—Flatulence—Epirubicin—urinary bladder cancer	0.000243	0.000437	CcSEcCtD
Zaleplon—CYP3A7—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000242	0.00829	CbGpPWpGaD
Zaleplon—Tension—Epirubicin—urinary bladder cancer	0.000242	0.000435	CcSEcCtD
Zaleplon—Dysgeusia—Epirubicin—urinary bladder cancer	0.000242	0.000435	CcSEcCtD
Zaleplon—Nervousness—Epirubicin—urinary bladder cancer	0.00024	0.000431	CcSEcCtD
Zaleplon—Back pain—Epirubicin—urinary bladder cancer	0.000239	0.000429	CcSEcCtD
Zaleplon—Malaise—Methotrexate—urinary bladder cancer	0.000238	0.000428	CcSEcCtD
Zaleplon—Dizziness—Etoposide—urinary bladder cancer	0.000238	0.000427	CcSEcCtD
Zaleplon—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000237	0.000426	CcSEcCtD
Zaleplon—Vertigo—Methotrexate—urinary bladder cancer	0.000237	0.000426	CcSEcCtD
Zaleplon—Chills—Doxorubicin—urinary bladder cancer	0.000236	0.000423	CcSEcCtD
Zaleplon—GABRA2—Ion channel transport—TRPV1—urinary bladder cancer	0.000235	0.00805	CbGpPWpGaD
Zaleplon—GABRB3—Ion channel transport—TRPV1—urinary bladder cancer	0.000234	0.00799	CbGpPWpGaD
Zaleplon—Nausea—Cisplatin—urinary bladder cancer	0.000233	0.000419	CcSEcCtD
Zaleplon—Alopecia—Doxorubicin—urinary bladder cancer	0.000232	0.000417	CcSEcCtD
Zaleplon—Mental disorder—Doxorubicin—urinary bladder cancer	0.00023	0.000413	CcSEcCtD
Zaleplon—GABRG2—Ion channel transport—TRPV1—urinary bladder cancer	0.00023	0.00785	CbGpPWpGaD
Zaleplon—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000229	0.000412	CcSEcCtD
Zaleplon—Malnutrition—Doxorubicin—urinary bladder cancer	0.000229	0.000411	CcSEcCtD
Zaleplon—Anaemia—Epirubicin—urinary bladder cancer	0.000228	0.00041	CcSEcCtD
Zaleplon—CYP3A5—Biological oxidations—GSTZ1—urinary bladder cancer	0.000228	0.00778	CbGpPWpGaD
Zaleplon—Agitation—Epirubicin—urinary bladder cancer	0.000227	0.000408	CcSEcCtD
Zaleplon—Rash—Etoposide—urinary bladder cancer	0.000227	0.000407	CcSEcCtD
Zaleplon—Dermatitis—Etoposide—urinary bladder cancer	0.000227	0.000407	CcSEcCtD
Zaleplon—Headache—Etoposide—urinary bladder cancer	0.000225	0.000405	CcSEcCtD
Zaleplon—Flatulence—Doxorubicin—urinary bladder cancer	0.000225	0.000405	CcSEcCtD
Zaleplon—Myalgia—Methotrexate—urinary bladder cancer	0.000225	0.000404	CcSEcCtD
Zaleplon—Chest pain—Methotrexate—urinary bladder cancer	0.000225	0.000404	CcSEcCtD
Zaleplon—Arthralgia—Methotrexate—urinary bladder cancer	0.000225	0.000404	CcSEcCtD
Zaleplon—CYP3A5—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000224	0.00767	CbGpPWpGaD
Zaleplon—Tension—Doxorubicin—urinary bladder cancer	0.000224	0.000403	CcSEcCtD
Zaleplon—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000224	0.000402	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000223	0.000401	CcSEcCtD
Zaleplon—Malaise—Epirubicin—urinary bladder cancer	0.000223	0.0004	CcSEcCtD
Zaleplon—Discomfort—Methotrexate—urinary bladder cancer	0.000222	0.000399	CcSEcCtD
Zaleplon—Nervousness—Doxorubicin—urinary bladder cancer	0.000222	0.000399	CcSEcCtD
Zaleplon—Vertigo—Epirubicin—urinary bladder cancer	0.000222	0.000399	CcSEcCtD
Zaleplon—Syncope—Epirubicin—urinary bladder cancer	0.000221	0.000398	CcSEcCtD
Zaleplon—Back pain—Doxorubicin—urinary bladder cancer	0.000221	0.000397	CcSEcCtD
Zaleplon—Palpitations—Epirubicin—urinary bladder cancer	0.000218	0.000392	CcSEcCtD
Zaleplon—Confusional state—Methotrexate—urinary bladder cancer	0.000217	0.00039	CcSEcCtD
Zaleplon—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000217	0.00039	CcSEcCtD
Zaleplon—CYP3A5—Biological oxidations—GSTO2—urinary bladder cancer	0.000216	0.00738	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—NAT1—urinary bladder cancer	0.000216	0.00738	CbGpPWpGaD
Zaleplon—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000215	0.00737	CbGpPWpGaD
Zaleplon—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000215	0.000387	CcSEcCtD
Zaleplon—Nausea—Etoposide—urinary bladder cancer	0.000214	0.000384	CcSEcCtD
Zaleplon—Hypertension—Epirubicin—urinary bladder cancer	0.000213	0.000383	CcSEcCtD
Zaleplon—CYP3A5—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000213	0.00728	CbGpPWpGaD
Zaleplon—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000212	0.000381	CcSEcCtD
Zaleplon—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000211	0.00038	CcSEcCtD
Zaleplon—Anaemia—Doxorubicin—urinary bladder cancer	0.000211	0.000379	CcSEcCtD
Zaleplon—Arthralgia—Epirubicin—urinary bladder cancer	0.00021	0.000378	CcSEcCtD
Zaleplon—Myalgia—Epirubicin—urinary bladder cancer	0.00021	0.000378	CcSEcCtD
Zaleplon—Chest pain—Epirubicin—urinary bladder cancer	0.00021	0.000378	CcSEcCtD
Zaleplon—Agitation—Doxorubicin—urinary bladder cancer	0.00021	0.000377	CcSEcCtD
Zaleplon—Anxiety—Epirubicin—urinary bladder cancer	0.00021	0.000376	CcSEcCtD
Zaleplon—Skin disorder—Methotrexate—urinary bladder cancer	0.000209	0.000376	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000209	0.000375	CcSEcCtD
Zaleplon—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000208	0.000374	CcSEcCtD
Zaleplon—Discomfort—Epirubicin—urinary bladder cancer	0.000208	0.000373	CcSEcCtD
Zaleplon—Malaise—Doxorubicin—urinary bladder cancer	0.000206	0.00037	CcSEcCtD
Zaleplon—Dry mouth—Epirubicin—urinary bladder cancer	0.000206	0.000369	CcSEcCtD
Zaleplon—Vertigo—Doxorubicin—urinary bladder cancer	0.000205	0.000369	CcSEcCtD
Zaleplon—Anorexia—Methotrexate—urinary bladder cancer	0.000205	0.000369	CcSEcCtD
Zaleplon—Syncope—Doxorubicin—urinary bladder cancer	0.000205	0.000368	CcSEcCtD
Zaleplon—Confusional state—Epirubicin—urinary bladder cancer	0.000203	0.000365	CcSEcCtD
Zaleplon—Palpitations—Doxorubicin—urinary bladder cancer	0.000202	0.000363	CcSEcCtD
Zaleplon—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000202	0.000362	CcSEcCtD
Zaleplon—Oedema—Epirubicin—urinary bladder cancer	0.000202	0.000362	CcSEcCtD
Zaleplon—Hypotension—Methotrexate—urinary bladder cancer	0.000201	0.000362	CcSEcCtD
Zaleplon—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000201	0.000361	CcSEcCtD
Zaleplon—GABRA1—Ion channel transport—TRPV1—urinary bladder cancer	0.000201	0.00686	CbGpPWpGaD
Zaleplon—Shock—Epirubicin—urinary bladder cancer	0.000198	0.000356	CcSEcCtD
Zaleplon—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000198	0.000355	CcSEcCtD
Zaleplon—CYP3A5—Biological oxidations—UGT2B7—urinary bladder cancer	0.000197	0.00675	CbGpPWpGaD
Zaleplon—Hypertension—Doxorubicin—urinary bladder cancer	0.000197	0.000354	CcSEcCtD
Zaleplon—Tachycardia—Epirubicin—urinary bladder cancer	0.000197	0.000353	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000196	0.000353	CcSEcCtD
Zaleplon—Skin disorder—Epirubicin—urinary bladder cancer	0.000196	0.000352	CcSEcCtD
Zaleplon—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000195	0.00035	CcSEcCtD
Zaleplon—Insomnia—Methotrexate—urinary bladder cancer	0.000195	0.00035	CcSEcCtD
Zaleplon—CYP3A5—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000195	0.00665	CbGpPWpGaD
Zaleplon—Chest pain—Doxorubicin—urinary bladder cancer	0.000195	0.00035	CcSEcCtD
Zaleplon—Myalgia—Doxorubicin—urinary bladder cancer	0.000195	0.00035	CcSEcCtD
Zaleplon—Arthralgia—Doxorubicin—urinary bladder cancer	0.000195	0.00035	CcSEcCtD
Zaleplon—Anxiety—Doxorubicin—urinary bladder cancer	0.000194	0.000348	CcSEcCtD
Zaleplon—Paraesthesia—Methotrexate—urinary bladder cancer	0.000193	0.000347	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000193	0.000347	CcSEcCtD
Zaleplon—Discomfort—Doxorubicin—urinary bladder cancer	0.000192	0.000345	CcSEcCtD
Zaleplon—Anorexia—Epirubicin—urinary bladder cancer	0.000192	0.000345	CcSEcCtD
Zaleplon—Dyspnoea—Methotrexate—urinary bladder cancer	0.000192	0.000345	CcSEcCtD
Zaleplon—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000192	0.00656	CbGpPWpGaD
Zaleplon—Somnolence—Methotrexate—urinary bladder cancer	0.000191	0.000344	CcSEcCtD
Zaleplon—Dry mouth—Doxorubicin—urinary bladder cancer	0.00019	0.000342	CcSEcCtD
Zaleplon—Dyspepsia—Methotrexate—urinary bladder cancer	0.00019	0.000341	CcSEcCtD
Zaleplon—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000189	0.00647	CbGpPWpGaD
Zaleplon—Hypotension—Epirubicin—urinary bladder cancer	0.000188	0.000338	CcSEcCtD
Zaleplon—Confusional state—Doxorubicin—urinary bladder cancer	0.000188	0.000338	CcSEcCtD
Zaleplon—Decreased appetite—Methotrexate—urinary bladder cancer	0.000187	0.000336	CcSEcCtD
Zaleplon—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000186	0.000335	CcSEcCtD
Zaleplon—Oedema—Doxorubicin—urinary bladder cancer	0.000186	0.000335	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000186	0.000334	CcSEcCtD
Zaleplon—Pain—Methotrexate—urinary bladder cancer	0.000184	0.000331	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000184	0.00033	CcSEcCtD
Zaleplon—Shock—Doxorubicin—urinary bladder cancer	0.000183	0.00033	CcSEcCtD
Zaleplon—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000183	0.000329	CcSEcCtD
Zaleplon—Insomnia—Epirubicin—urinary bladder cancer	0.000182	0.000328	CcSEcCtD
Zaleplon—Tachycardia—Doxorubicin—urinary bladder cancer	0.000182	0.000327	CcSEcCtD
Zaleplon—Skin disorder—Doxorubicin—urinary bladder cancer	0.000181	0.000325	CcSEcCtD
Zaleplon—Paraesthesia—Epirubicin—urinary bladder cancer	0.000181	0.000325	CcSEcCtD
Zaleplon—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00018	0.000324	CcSEcCtD
Zaleplon—Dyspnoea—Epirubicin—urinary bladder cancer	0.00018	0.000323	CcSEcCtD
Zaleplon—Somnolence—Epirubicin—urinary bladder cancer	0.000179	0.000322	CcSEcCtD
Zaleplon—Anorexia—Doxorubicin—urinary bladder cancer	0.000178	0.000319	CcSEcCtD
Zaleplon—CYP3A5—Biological oxidations—CYP4B1—urinary bladder cancer	0.000178	0.00607	CbGpPWpGaD
Zaleplon—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000177	0.000319	CcSEcCtD
Zaleplon—Dyspepsia—Epirubicin—urinary bladder cancer	0.000177	0.000319	CcSEcCtD
Zaleplon—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000176	0.000316	CcSEcCtD
Zaleplon—CYP3A5—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000175	0.00599	CbGpPWpGaD
Zaleplon—Decreased appetite—Epirubicin—urinary bladder cancer	0.000175	0.000315	CcSEcCtD
Zaleplon—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	0.000175	0.00598	CbGpPWpGaD
Zaleplon—Hypotension—Doxorubicin—urinary bladder cancer	0.000174	0.000313	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000174	0.000313	CcSEcCtD
Zaleplon—Pain—Epirubicin—urinary bladder cancer	0.000172	0.00031	CcSEcCtD
Zaleplon—Constipation—Epirubicin—urinary bladder cancer	0.000172	0.00031	CcSEcCtD
Zaleplon—Urticaria—Methotrexate—urinary bladder cancer	0.000171	0.000307	CcSEcCtD
Zaleplon—Body temperature increased—Methotrexate—urinary bladder cancer	0.00017	0.000306	CcSEcCtD
Zaleplon—Abdominal pain—Methotrexate—urinary bladder cancer	0.00017	0.000306	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00017	0.000305	CcSEcCtD
Zaleplon—Insomnia—Doxorubicin—urinary bladder cancer	0.000169	0.000303	CcSEcCtD
Zaleplon—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000167	0.000301	CcSEcCtD
Zaleplon—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000166	0.000299	CcSEcCtD
Zaleplon—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000166	0.000298	CcSEcCtD
Zaleplon—Somnolence—Doxorubicin—urinary bladder cancer	0.000166	0.000298	CcSEcCtD
Zaleplon—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000165	0.00565	CbGpPWpGaD
Zaleplon—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000165	0.000296	CcSEcCtD
Zaleplon—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000164	0.000295	CcSEcCtD
Zaleplon—CYP3A7—Biological oxidations—NAT2—urinary bladder cancer	0.000164	0.00559	CbGpPWpGaD
Zaleplon—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000162	0.000291	CcSEcCtD
Zaleplon—CYP3A7—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000161	0.00551	CbGpPWpGaD
Zaleplon—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000161	0.000289	CcSEcCtD
Zaleplon—Urticaria—Epirubicin—urinary bladder cancer	0.00016	0.000288	CcSEcCtD
Zaleplon—Constipation—Doxorubicin—urinary bladder cancer	0.000159	0.000287	CcSEcCtD
Zaleplon—Pain—Doxorubicin—urinary bladder cancer	0.000159	0.000287	CcSEcCtD
Zaleplon—Abdominal pain—Epirubicin—urinary bladder cancer	0.000159	0.000286	CcSEcCtD
Zaleplon—Body temperature increased—Epirubicin—urinary bladder cancer	0.000159	0.000286	CcSEcCtD
Zaleplon—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000156	0.00532	CbGpPWpGaD
Zaleplon—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000155	0.0053	CbGpPWpGaD
Zaleplon—Asthenia—Methotrexate—urinary bladder cancer	0.000155	0.000278	CcSEcCtD
Zaleplon—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000154	0.000276	CcSEcCtD
Zaleplon—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000152	0.000274	CcSEcCtD
Zaleplon—Pruritus—Methotrexate—urinary bladder cancer	0.000152	0.000274	CcSEcCtD
Zaleplon—GABRB2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000148	0.00507	CbGpPWpGaD
Zaleplon—Urticaria—Doxorubicin—urinary bladder cancer	0.000148	0.000266	CcSEcCtD
Zaleplon—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000147	0.000265	CcSEcCtD
Zaleplon—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000147	0.000265	CcSEcCtD
Zaleplon—Asthenia—Epirubicin—urinary bladder cancer	0.000145	0.00026	CcSEcCtD
Zaleplon—Pruritus—Epirubicin—urinary bladder cancer	0.000143	0.000256	CcSEcCtD
Zaleplon—Dizziness—Methotrexate—urinary bladder cancer	0.000142	0.000256	CcSEcCtD
Zaleplon—GABRA2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000139	0.00475	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000138	0.00472	CbGpPWpGaD
Zaleplon—Rash—Methotrexate—urinary bladder cancer	0.000136	0.000244	CcSEcCtD
Zaleplon—AOX1—Disease—GSTO2—urinary bladder cancer	0.000136	0.00464	CbGpPWpGaD
Zaleplon—Dermatitis—Methotrexate—urinary bladder cancer	0.000136	0.000244	CcSEcCtD
Zaleplon—GABRG2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000136	0.00464	CbGpPWpGaD
Zaleplon—Headache—Methotrexate—urinary bladder cancer	0.000135	0.000242	CcSEcCtD
Zaleplon—Asthenia—Doxorubicin—urinary bladder cancer	0.000134	0.00024	CcSEcCtD
Zaleplon—Dizziness—Epirubicin—urinary bladder cancer	0.000133	0.000239	CcSEcCtD
Zaleplon—Pruritus—Doxorubicin—urinary bladder cancer	0.000132	0.000237	CcSEcCtD
Zaleplon—CYP3A7—Biological oxidations—HPGDS—urinary bladder cancer	0.000131	0.00447	CbGpPWpGaD
Zaleplon—Nausea—Methotrexate—urinary bladder cancer	0.000128	0.00023	CcSEcCtD
Zaleplon—Rash—Epirubicin—urinary bladder cancer	0.000127	0.000228	CcSEcCtD
Zaleplon—Dermatitis—Epirubicin—urinary bladder cancer	0.000127	0.000228	CcSEcCtD
Zaleplon—CYP3A7—Biological oxidations—GSTT1—urinary bladder cancer	0.000127	0.00434	CbGpPWpGaD
Zaleplon—Headache—Epirubicin—urinary bladder cancer	0.000126	0.000227	CcSEcCtD
Zaleplon—Dizziness—Doxorubicin—urinary bladder cancer	0.000123	0.000222	CcSEcCtD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000123	0.00421	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GSTZ1—urinary bladder cancer	0.00012	0.0041	CbGpPWpGaD
Zaleplon—Nausea—Epirubicin—urinary bladder cancer	0.00012	0.000215	CcSEcCtD
Zaleplon—GABRA1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000119	0.00405	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—NAT2—urinary bladder cancer	0.000118	0.00404	CbGpPWpGaD
Zaleplon—Rash—Doxorubicin—urinary bladder cancer	0.000118	0.000211	CcSEcCtD
Zaleplon—Dermatitis—Doxorubicin—urinary bladder cancer	0.000117	0.000211	CcSEcCtD
Zaleplon—Headache—Doxorubicin—urinary bladder cancer	0.000117	0.00021	CcSEcCtD
Zaleplon—CYP3A5—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000117	0.00399	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GSTO2—urinary bladder cancer	0.000114	0.00389	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—NAT1—urinary bladder cancer	0.000114	0.00389	CbGpPWpGaD
Zaleplon—GABRB2—Orphan transporters—CREBBP—urinary bladder cancer	0.000113	0.00387	CbGpPWpGaD
Zaleplon—Nausea—Doxorubicin—urinary bladder cancer	0.000111	0.000199	CcSEcCtD
Zaleplon—GABRB2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000107	0.00366	CbGpPWpGaD
Zaleplon—GABRA2—Orphan transporters—CREBBP—urinary bladder cancer	0.000106	0.00363	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000106	0.00362	CbGpPWpGaD
Zaleplon—AOX1—Disease—SLC19A1—urinary bladder cancer	0.000106	0.00361	CbGpPWpGaD
Zaleplon—GABRB3—Orphan transporters—CREBBP—urinary bladder cancer	0.000105	0.0036	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000104	0.00357	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—UGT2B7—urinary bladder cancer	0.000104	0.00355	CbGpPWpGaD
Zaleplon—GABRG2—Orphan transporters—CREBBP—urinary bladder cancer	0.000103	0.00354	CbGpPWpGaD
Zaleplon—AOX1—Disease—PRSS3—urinary bladder cancer	0.000103	0.00352	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.0001	0.00344	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.0001	0.00343	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.0001	0.00343	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	9.98e-05	0.00341	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	9.89e-05	0.00338	CbGpPWpGaD
Zaleplon—AOX1—Disease—HDAC4—urinary bladder cancer	9.81e-05	0.00336	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	9.8e-05	0.00335	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—HPGDS—urinary bladder cancer	9.45e-05	0.00323	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—CYP4B1—urinary bladder cancer	9.36e-05	0.0032	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	9.17e-05	0.00314	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—GSTT1—urinary bladder cancer	9.17e-05	0.00313	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	9.05e-05	0.00309	CbGpPWpGaD
Zaleplon—GABRA1—Orphan transporters—CREBBP—urinary bladder cancer	9.04e-05	0.00309	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—SLC19A1—urinary bladder cancer	8.84e-05	0.00302	CbGpPWpGaD
Zaleplon—CYP3A7—Biological oxidations—GSTP1—urinary bladder cancer	8.79e-05	0.00301	CbGpPWpGaD
Zaleplon—GABRB2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.74e-05	0.00299	CbGpPWpGaD
Zaleplon—CYP3A7—Metapathway biotransformation—GSTP1—urinary bladder cancer	8.67e-05	0.00296	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PRSS3—urinary bladder cancer	8.61e-05	0.00295	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8.57e-05	0.00293	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	8.26e-05	0.00282	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.19e-05	0.0028	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	8.15e-05	0.00279	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.14e-05	0.00278	CbGpPWpGaD
Zaleplon—CYP3A7—Biological oxidations—GSTM1—urinary bladder cancer	8.08e-05	0.00276	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.99e-05	0.00273	CbGpPWpGaD
Zaleplon—CYP3A7—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.97e-05	0.00272	CbGpPWpGaD
Zaleplon—AOX1—Disease—LIG1—urinary bladder cancer	7.8e-05	0.00267	CbGpPWpGaD
Zaleplon—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	7.12e-05	0.00243	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.99e-05	0.00239	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—TYMP—urinary bladder cancer	6.89e-05	0.00235	CbGpPWpGaD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	6.54e-05	0.00224	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	6.35e-05	0.00217	CbGpPWpGaD
Zaleplon—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.27e-05	0.00214	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—NAT2—urinary bladder cancer	6.23e-05	0.00213	CbGpPWpGaD
Zaleplon—AOX1—Disease—ENO2—urinary bladder cancer	5.95e-05	0.00203	CbGpPWpGaD
Zaleplon—GABRB2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.9e-05	0.00202	CbGpPWpGaD
Zaleplon—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	5.84e-05	0.002	CbGpPWpGaD
Zaleplon—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.76e-05	0.00197	CbGpPWpGaD
Zaleplon—AOX1—Disease—RBX1—urinary bladder cancer	5.64e-05	0.00193	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.53e-05	0.00189	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.5e-05	0.00188	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	5.5e-05	0.00188	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	5.42e-05	0.00185	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.4e-05	0.00185	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	5.38e-05	0.00184	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—SRC—urinary bladder cancer	5.38e-05	0.00184	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—RRM2—urinary bladder cancer	5.38e-05	0.00184	CbGpPWpGaD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	5.19e-05	0.00178	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	5.1e-05	0.00175	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—NAT1—urinary bladder cancer	5.1e-05	0.00175	CbGpPWpGaD
Zaleplon—AOX1—Disease—JAG1—urinary bladder cancer	5.04e-05	0.00172	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—HPGDS—urinary bladder cancer	4.98e-05	0.0017	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—ENO2—urinary bladder cancer	4.98e-05	0.0017	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GSTT1—urinary bladder cancer	4.83e-05	0.00165	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.72e-05	0.00161	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	4.67e-05	0.0016	CbGpPWpGaD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	4.45e-05	0.00152	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	4.39e-05	0.0015	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	4.26e-05	0.00146	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	4.2e-05	0.00144	CbGpPWpGaD
Zaleplon—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	4.16e-05	0.00142	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—NQO1—urinary bladder cancer	4.01e-05	0.00137	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	3.97e-05	0.00136	CbGpPWpGaD
Zaleplon—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	3.9e-05	0.00133	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	3.89e-05	0.00133	CbGpPWpGaD
Zaleplon—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	3.87e-05	0.00132	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	3.87e-05	0.00132	CbGpPWpGaD
Zaleplon—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	3.8e-05	0.0013	CbGpPWpGaD
Zaleplon—GABRB3—BDNF signaling pathway—HRAS—urinary bladder cancer	3.79e-05	0.00129	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	3.69e-05	0.00126	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—NAT1—urinary bladder cancer	3.69e-05	0.00126	CbGpPWpGaD
Zaleplon—AOX1—Disease—NCOR1—urinary bladder cancer	3.67e-05	0.00126	CbGpPWpGaD
Zaleplon—GABRA1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	3.61e-05	0.00124	CbGpPWpGaD
Zaleplon—AOX1—Disease—ERCC2—urinary bladder cancer	3.45e-05	0.00118	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	3.37e-05	0.00115	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GSTP1—urinary bladder cancer	3.35e-05	0.00114	CbGpPWpGaD
Zaleplon—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	3.32e-05	0.00114	CbGpPWpGaD
Zaleplon—AOX1—Disease—MTHFR—urinary bladder cancer	3.25e-05	0.00111	CbGpPWpGaD
Zaleplon—AOX1—Disease—TERT—urinary bladder cancer	3.24e-05	0.00111	CbGpPWpGaD
Zaleplon—GABRB2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	3.13e-05	0.00107	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—TYMS—urinary bladder cancer	3.11e-05	0.00106	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—TYMP—urinary bladder cancer	3.09e-05	0.00106	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GSTM1—urinary bladder cancer	3.08e-05	0.00105	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—NCOR1—urinary bladder cancer	3.08e-05	0.00105	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	3.04e-05	0.00104	CbGpPWpGaD
Zaleplon—AOX1—Disease—FGFR3—urinary bladder cancer	2.97e-05	0.00102	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.95e-05	0.00101	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—GPX1—urinary bladder cancer	2.95e-05	0.00101	CbGpPWpGaD
Zaleplon—GABRA2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.93e-05	0.001	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.91e-05	0.000996	CbGpPWpGaD
Zaleplon—GABRB3—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.91e-05	0.000995	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—ERCC2—urinary bladder cancer	2.89e-05	0.000989	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	2.87e-05	0.000981	CbGpPWpGaD
Zaleplon—GABRG2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.86e-05	0.000977	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—NAT2—urinary bladder cancer	2.8e-05	0.000956	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	2.8e-05	0.000956	CbGpPWpGaD
Zaleplon—GABRB2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.76e-05	0.000944	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—MTHFR—urinary bladder cancer	2.72e-05	0.000929	CbGpPWpGaD
Zaleplon—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.71e-05	0.000928	CbGpPWpGaD
Zaleplon—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.68e-05	0.000915	CbGpPWpGaD
Zaleplon—GABRA2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.59e-05	0.000885	CbGpPWpGaD
Zaleplon—GABRB3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.57e-05	0.00088	CbGpPWpGaD
Zaleplon—AOX1—Disease—CREBBP—urinary bladder cancer	2.53e-05	0.000865	CbGpPWpGaD
Zaleplon—GABRG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.53e-05	0.000864	CbGpPWpGaD
Zaleplon—GABRA1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.5e-05	0.000854	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—RRM2—urinary bladder cancer	2.41e-05	0.000825	CbGpPWpGaD
Zaleplon—GABRB2—Neuronal System—HRAS—urinary bladder cancer	2.39e-05	0.000819	CbGpPWpGaD
Zaleplon—AOX1—Disease—RHOA—urinary bladder cancer	2.29e-05	0.000782	CbGpPWpGaD
Zaleplon—GABRA2—Neuronal System—HRAS—urinary bladder cancer	2.24e-05	0.000768	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	2.24e-05	0.000764	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ENO2—urinary bladder cancer	2.24e-05	0.000764	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—TYMP—urinary bladder cancer	2.24e-05	0.000764	CbGpPWpGaD
Zaleplon—GABRB3—Neuronal System—HRAS—urinary bladder cancer	2.23e-05	0.000763	CbGpPWpGaD
Zaleplon—GABRA1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.21e-05	0.000755	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PPARG—urinary bladder cancer	2.2e-05	0.000754	CbGpPWpGaD
Zaleplon—GABRG2—Neuronal System—HRAS—urinary bladder cancer	2.19e-05	0.000749	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	2.17e-05	0.000741	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—CREBBP—urinary bladder cancer	2.12e-05	0.000724	CbGpPWpGaD
Zaleplon—AOX1—Disease—ERBB2—urinary bladder cancer	2.12e-05	0.000724	CbGpPWpGaD
Zaleplon—AOX1—Disease—PTGS2—urinary bladder cancer	2.07e-05	0.000708	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—NAT2—urinary bladder cancer	2.02e-05	0.000691	CbGpPWpGaD
Zaleplon—GABRA1—Neuronal System—HRAS—urinary bladder cancer	1.91e-05	0.000654	CbGpPWpGaD
Zaleplon—AOX1—Disease—CDKN1A—urinary bladder cancer	1.81e-05	0.000619	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.81e-05	0.000619	CbGpPWpGaD
Zaleplon—AOX1—Disease—PTEN—urinary bladder cancer	1.81e-05	0.000617	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—NQO1—urinary bladder cancer	1.8e-05	0.000616	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—RRM2—urinary bladder cancer	1.75e-05	0.000597	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PTGS2—urinary bladder cancer	1.73e-05	0.000593	CbGpPWpGaD
Zaleplon—AOX1—Disease—EP300—urinary bladder cancer	1.72e-05	0.000589	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.72e-05	0.000586	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.72e-05	0.000586	CbGpPWpGaD
Zaleplon—AOX1—Disease—SRC—urinary bladder cancer	1.67e-05	0.000573	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ENO2—urinary bladder cancer	1.62e-05	0.000553	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	1.62e-05	0.000553	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.57e-05	0.000536	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.57e-05	0.000536	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—PTEN—urinary bladder cancer	1.51e-05	0.000517	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	1.5e-05	0.000514	CbGpPWpGaD
Zaleplon—AOX1—Disease—MYC—urinary bladder cancer	1.5e-05	0.000513	CbGpPWpGaD
Zaleplon—AOX1—Disease—EGFR—urinary bladder cancer	1.47e-05	0.000502	CbGpPWpGaD
Zaleplon—AOX1—Metabolism—EP300—urinary bladder cancer	1.44e-05	0.000493	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.41e-05	0.000483	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—TYMS—urinary bladder cancer	1.4e-05	0.000478	CbGpPWpGaD
Zaleplon—AOX1—Disease—KRAS—urinary bladder cancer	1.39e-05	0.000474	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	1.38e-05	0.000472	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	1.38e-05	0.000472	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.33e-05	0.000456	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.32e-05	0.000452	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.3e-05	0.000445	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.3e-05	0.000444	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.3e-05	0.000444	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.22e-05	0.000417	CbGpPWpGaD
Zaleplon—AOX1—Disease—HRAS—urinary bladder cancer	1.18e-05	0.000403	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.09e-05	0.000371	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.04e-05	0.000355	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.01e-05	0.000345	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	9.98e-06	0.000341	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	9.98e-06	0.000341	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PPARG—urinary bladder cancer	9.9e-06	0.000338	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—GPX1—urinary bladder cancer	9.56e-06	0.000327	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	9.51e-06	0.000325	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—NAT2—urinary bladder cancer	9.4e-06	0.000321	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	9.39e-06	0.000321	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	8.82e-06	0.000302	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—RRM2—urinary bladder cancer	8.11e-06	0.000277	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	7.79e-06	0.000266	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	7.51e-06	0.000257	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ENO2—urinary bladder cancer	7.51e-06	0.000257	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	7.29e-06	0.000249	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PPARG—urinary bladder cancer	7.16e-06	0.000245	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	6.87e-06	0.000235	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—PTEN—urinary bladder cancer	6.79e-06	0.000232	CbGpPWpGaD
Zaleplon—CYP3A7—Metabolism—EP300—urinary bladder cancer	6.48e-06	0.000221	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.06e-06	0.000207	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	5.63e-06	0.000192	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.05e-06	0.000173	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—PTEN—urinary bladder cancer	4.91e-06	0.000168	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.7e-06	0.000161	CbGpPWpGaD
Zaleplon—CYP3A5—Metabolism—EP300—urinary bladder cancer	4.68e-06	0.00016	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.64e-06	0.000159	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.64e-06	0.000159	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.45e-06	0.000152	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.36e-06	0.000149	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.1e-06	0.00014	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.33e-06	0.000114	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.2e-06	0.000109	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.62e-06	8.95e-05	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.28e-06	7.8e-05	CbGpPWpGaD
Zaleplon—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.18e-06	7.44e-05	CbGpPWpGaD
